4,4-二甲基环己烯-1-基硼酸 | 865869-28-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硼酸衍生物
• 中文名称: 4,4-二甲基环己烯-1-基硼酸
• 中文别名: 4,4-二甲基环己烯-1-硼酸
• 英文名称: (4,4-dimethylcyclohex-1-en-1-yl)boronic acid
• 英文别名: 4,4-dimethylcyclohex-1-enylboronic acid；4,4-Dimethylcyclohexen-1-ylboronic acid；(4,4-dimethylcyclohexen-1-yl)boronic acid
• CAS: 865869-28-9
• 化学式: C₈H₁₅BO₂
• mdl: MFCD07363758
• 分子量: 154.017
• InChiKey: HWFBGGLUEZIDOE-UHFFFAOYSA-N

物化性质

• 熔点：
  152-154
• 沸点：
  264.1±33.0 °C(Predicted)
• 密度：
  1.00±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.72
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P210,P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P332+P313,P337+P313,P362,P370+P378,P403+P233,P403+P235,P405,P501
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4,4-Dimethylcyclohexen-1-ylboronic acid
Product Name:
Synonyms: 4,4-Dimethyl-1-cyclohexen-1-ylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4,4-Dimethylcyclohexen-1-ylboronic acid
Ingredient name:
CAS number: 865869-28-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H15BO2
Molecular weight: 154.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,4-二甲基环己烯-1-基硼酸 在 trans-bis(triphenylphosphine)palladium dichloride potassium phosphate 、 N-溴代丁二酰亚胺(NBS) 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 氘代氯仿 、 水 为溶剂， 反应 26.5h， 生成 5-(3-chloro-pyridin-4-yl)-4-(4,4-dimethylcyclohex-1-en-1-yl)-pyrimidin-2-amine
  参考文献：
  名称：

  [EN] GEM-DISUBSTITUTED AND SPIROCYCLIC AMINO PYRIDINES/PYRIMIDINES AS CELL CYCLE INHIBITORS
  [FR] PYRIDINES/PYRIMIDINES AMINO SPIROCYCLIQUES ET DISUBSTITUÉES PAR GEM EN TANT QU'INHIBITEURS DE CYCLE CELLULAIRE

  摘要：

  提供了一些化合物、药物组合物和方法，这些化合物、药物组合物和方法可用于治疗CDK4介导的疾病，如癌症。所述化合物是 gem-二取代或螺环的吡啶、嘧啶和三嗪衍生物。

  公开号：

  WO2009126584A1
• 作为产物：
  描述：

  4,4-二甲基环己酮 在 sodium periodate 、 正丁基锂 、 四甲基乙二胺 、 ammonium acetate 、 水 作用下， 以 甲醇 、 正己烷 、 丙酮 为溶剂， 反应 5.0h， 生成 4,4-二甲基环己烯-1-基硼酸
  参考文献：
  名称：

  铜催化的烯基硼酸的三或四官能度制备四氢咔唑-1-酮和吲哚[2,3-a]咔唑

  摘要：

  我们描述了烯基硼酸的三或四官能化的级联策略，以制备具有N的高收率的各种四氢咔唑-1-酮和吲哚[2,3- a ]咔唑-羟基苯并三嗪-4-酮（HOOBT）和芳基肼分别作为氧和氮源。机理研究表明，多米诺反应在一锅法反应中经过五个步骤，经历了铜催化的Chan-Lam反应，[2,3]重排，亲核取代，氧化和顺序[3,3]重排。该反应显示出广泛的底物范围，并且可以耐受多种官能团。更重要的是，该反应易于以克为单位进行，并且产物可以通过简单的萃取，洗涤和重结晶进行纯化，而无需快速柱色谱。本协议的特点是易于获得的起始原料，高位标记的功能化，一锅中的五步串联，多个C–C / C–O / C–N键形成以及吲哚图案的多样性。

  DOI：

  10.1039/d0gc01514h

文献信息

• METHOD OF INHIBITING C-KIT KINASE
  申请人：Illig R. Carl

  公开号：US20080051402A1

  公开（公告）日：2008-02-28

  A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or pharmaceutically acceptable salt thereof. The present invention is further directed to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明提供了一种减少或抑制细胞或主体中C-KIT激酶活性的方法，以及使用本发明的化合物预防或治疗主体中的细胞增殖障碍和/或与C-KIT相关疾病的应用：或其溶剂化物、水合物、互变异构体或药用可接受盐。本发明进一步涉及治疗癌症和其他细胞增殖障碍等条件的方法。
• Interrupted Fischer-Indole Intermediates via Oxyarylation of Alkenyl Boronic Acids
  作者：Heng-Yen Wang、Laura L. Anderson

  DOI：10.1021/ol401416r

  日期：2013.7.5

  The oxyarylation of alkenyl boronic acids with N-arylbenzhydroxamic acids has been achieved under both copper-mediated and copper-catalyzed conditions to provide access to interrupted Fischer-indole intermediates. This transformation is believed to proceed through a copper-promoted C–O bond forming event followed by a [3,3] rearrangement. The scope of the method is described and mechanistic experiments

  在铜介导的和铜催化的条件下，已经实现了烯基硼酸与N-芳基苯并异羟肟酸的氧化芳基化，以提供接近的费歇尔-吲哚中间体的途径。据认为，这种转变是通过铜促进的C–O键形成事件继之以[3,3]重排而进行的。描述了该方法的范围并讨论了机械实验。
• [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014164467A1

  公开（公告）日：2014-10-09

  The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.

  该披露通常涉及到I式化合物，包括用于治疗人类免疫缺陷病毒（HIV）感染的组合物和方法。该披露提供了HIV的新型抑制剂，含有这些化合物的药物组合物，以及在治疗HIV感染中使用这些化合物的方法。
• [EN] GLUCAGON ANTAGONISTS<br/>[FR] ANTAGONISTES DE GLUCAGON
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2010019830A1

  公开（公告）日：2010-02-18

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or Co- crystals and prodrugs thereof. Formula I

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体和前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或病情的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体和前药。公式I
• [EN] GLUCAGON ANTAGONISTS<br/>[FR] ANTAGONISTES DU GLUCAGON
  申请人：LIGAND PHARM INC

  公开号：WO2015191900A1

  公开（公告）日：2015-12-17

  Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance and hyperglycemia. Moreover, provided herein are methods of making or manufacturing compounds disclosed herein, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof.

  本文提供了化合物，包括其对映体纯形式，以及具有胰高血糖素受体拮抗剂或逆向激动剂活性的药用盐或共晶体及前药。此外，本文提供了包括这些化合物的药物组合物，以及治疗、预防、延缓发病时间或减少一种或多种胰高血糖素受体拮抗剂适用的疾病或症状的发展或进展风险的方法，包括I型和II型糖尿病、胰岛素抵抗和高血糖。此外，本文提供了制备或生产本文披露的化合物的方法，包括其对映体纯形式，以及药用盐或共晶体及前药。